When using a PD-L1 positivity cut-off of ≥5% of tumor cells, there were 76% (22 out of 29) PD-L1 positive AD patient samples which harbored one or more of the 5 LC tumor driver alterations. This evidence concerns the gene CD274 and laryngotracheoesophageal cleft.